Fostamatinib disodium hexahydrate

福他替尼二钠六水合物

Report date: 2026/04/30 20:00:20
NMEFirst In Class

Base Information

Drug NameFostamatinib disodium hexahydrate
Drug Alias Name福他替尼Fostamatinib sodiumFosDFostamatinib Disodium HydrateFostamatinib disodium +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinase
Therapy Area/IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Graft vs Host Disease +[30] 
Global Approved IndicationsThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/04/17
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRigel PharmaceuticalsJw Pharmaceutical CorpIkena Oncology Inc +[10] 
Inactive CompaniesAstrazeneca PlcNational Cancer InstituteAstrazeneca Ab
Active IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Myelodysplastic Syndromes +[15] 
Inactive IndicationsGraft vs Host DiseaseLupus Erythematosus, SystemicAnemia +[15] 

Other Information

ATC CodeB02BX09
Related LinksWikipediaDrugBankKEGG